Free Newsletter
Pharma layoffs near 35K in first half of 2010
The pharmaceutical industry has eliminated 34,987 positions so far this year, second only to the goverment in total number of layoffs in 2010. That's the bad news. The good news? Companies laid off just 830 people in June. That's a massive plunge from May when 6,943 jobs were eliminated.
Pharma Layoffs by Month, 2010
| Month | Layoffs |
| January | 8,170 |
| February | 25,875 |
| March | 308 |
| April | 1,049 |
| May | 6,943 |
| June | 830 |
| TOTAL | 34,987 |
Outplacement consultancy firm Challenger, Gray and Christmas observe that the economy could be turning around. "Job cuts this year have declined for each of the top-five job-cutting industries. Even cuts in the government and non-profit sector are down, albeit not as dramatically as the other leading job-cut sectors. This certainly bodes well for the job market as we enter the second half of 2010," said CEO John Challenger. Still, the economy has a long way to go before the job market is back on track. Though one million Americans were added to payrolls in the last six months, seven million more are still unemployed after losing their jobs during the recession.
Top Five Industries, Year to Date
| Industry | 2010 | 2009 |
| Government/Non-Profit |
98,776 |
102,302 |
| Pharmaceutical |
34,987 |
51,549 |
| Retail |
26,181 |
85,698 |
| Computer |
16,964 |
51,461 |
| Telecommunications |
16,005 |
20,848 |
Chart courtesy of Challenger, Gray and Christmas
- here's the layoffs release
Related Articles:
Report: Pharma cuts 6,943 jobs in May
Pharma layoffs plunge to just 308 in March
Pharma reports 26,000 layoffs in 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: